Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IAPP | P10997 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349330 | 1.00 | ALDH1A1 (0.40) | ALDH1A1LMNAIAPPPTGER4PTGER3 | |
| SCHEMBL8938495 | 0.80 | HTR5A (0.32) | HTR5A | |
| SCHEMBL9692553 | 0.77 | TAAR1 (0.38) | HTR5A | |
| SCHEMBL8938192 | 0.77 | HTR5A (0.32) | HTR5A | |
| SCHEMBL3771929 | 0.77 | HTR5A (0.33) | HTR5A | |
| SCHEMBL9691832 | 0.77 | HTR5A (0.33) | HTR5A | |
| SCHEMBL9692481 | 0.76 | TAAR1 (0.39) | — | |
| SCHEMBL8553459 | 0.75 | SMN1; SMN2 (0.35) | ALDH1A1LMNAHTR5AMAPTSMN1; SMN2 | |
| SCHEMBL6794782 | 0.75 | ADRA1A (0.42) | HTR5A | |
| SCHEMBL10402771 | 0.74 | HTR5A (0.33) | HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023051793-A1 | COMPOUND AS INHIBITOR OF COMPLEMENT FACTOR D, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 武汉朗来科技发展有限公司 | 2023-04-06 | — | — | WO | disclosed |